Merck & Company, Inc. · NYSE:MRK
Merck & — Shareholder Meeting (May 2025)
38 slides from Merck &'s shareholder meeting presentation, May 27, 2025
Slide 1: Annual Meeting of Shareholders
Annual Meeting of Shareholders Merck & Co., Inc., Rahway, N.J., USA May 27, 2025 1
Slide 2: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These state
Slide 3: Annual Meeting of Shareholders – Robert M. Davis
Annual Meeting of Shareholders Robert M. Davis Chairman, Chief Executive Officer and President 3
Slide 4: Nominees for Director
Nominees for Director Robert M. Douglas M. Mary Ellen Coe Pamela J. Craig Thomas H. Surendralal L. Risa J. Lavizzo- Davis Baker, Jr. Glocer Karsanbhai Mourey, M.D. Stephen L. Paul B. Patricia F. Christine E. Inge G. Thulin Kathy J. Warden Mayo, Ph.D. Rothman, M.D. Russo Seidman, M.D. 4
Slide 5: Executive team
Executive team Robert M. Davis Sanat Chattopadhyay Richard R. DeLuca, Jr. Cristal N. Downing Chirfi Guindo Betty Larson Dean Y. Li, M.D., Ph.D. Caroline Litchfield Jannie Oosthuizen Joseph Romanelli Dave Williams Jennifer Zachary 5
Slide 6: 6
6
Slide 7: Our Purpose
Our Purpose For more than 130 years, our Company has been guided by one clear and compelling purpose: putting patients first and using the power of leading-edge science to save and improve lives. 7
Slide 8: Full-year 2024 highlights
Full-year 2024 highlights Financial highlights (Non-GAAP)1 Human Health sales Full Year Ex-Exchange $57.4B 2024 % vs. Prior +7% +10% ex-exchange3 Sales $64.2 +10%3 Strong growth in KEYTRUDA and WELIREG as well as WINREVAIR and Net Income $19.4 N/M CAPVAXIVE launches Non-GAAP EPS2 $7.65 N/M Animal He
Slide 9: Momentum across diverse pipeline and portfolio
Momentum across diverse pipeline and portfolio Oncology Cardiometabolic Vaccines and infectious Animal Health disease diseases 9
Slide 10: Business development to augment strong pipeline
Business development to augment strong pipeline $40B+ invested in strategic business development* Completed in 2024 10 *Since 2021. BD figure includes upfront and milestone payments related to acquisitions, strategic collaborations and licensing agreements.
Slide 11: Committed to operating responsibly and delivering sustainable value
Committed to operating responsibly and delivering sustainable value Nearly half a billion reached $12 billion invested in U.S. $12 million in humanitarian aid with our medicines and vaccines in 2024 donated in 2024 manufacturing and R&D since 2018 11
Slide 12: 12
12
Slide 13: Annual Meeting of Shareholders – Dean Y. Li
Annual Meeting of Shareholders Dean Y. Li, M.D., Ph.D. Executive Vice President and President, Research Laboratories 13
Slide 14: Strengthening our pipeline and sustaining our business
Strengthening our pipeline and sustaining our business One Pipeline: Strategic priorities Diversify Expand across Invest in new oncology therapeutic areas technologies and capabilities 14
Slide 15: Continuing to advance our broad oncology program
Continuing to advance our broad oncology program May 30 – June 3, 2025 15
Slide 16: Building on our legacy of delivering for patients
Building on our legacy of delivering for patients Vaccines Infectious diseases Cardiometabolic HIV 16
Slide 17: Vaccines
Vaccines • 21-valent pneumococcal vaccine specifically designed for adults and covers the serotypes that are responsible for most cases of adult invasive pneumococcal disease • In U.S., helps protect against serotypes responsible for ~84 percent of invasive pneumococcal disease cases in adults 50 an
Slide 18: Clesrovimab
Infectious diseases Clesrovimab • Preventive, long-acting monoclonal antibody designed to protect infants from RSV disease for the duration of their first RSV season • Potential first and only RSV immunization for healthy and certain at-risk infants that uses the same dose regardless of weight • PDU
Slide 19: Cardiometabolic
Cardiometabolic • First activin signaling inhibitor approved for the treatment of certain patients with PAH • Announced detailed results from Phase 3 ZENITH trial. The primary endpoint showed a significant 76 percent reduction in risk of the composite of all-cause death, lung transplantation and PAH
Slide 20: Cardiometabolic: Enlicitide
Cardiometabolic Enlicitide • Investigational oral PCSK9 inhibitor for the treatment of hypercholesterolemia • New and potentially important option for a low-density, cholesterol-lowering pill • Ongoing Phase 3 program 20
Slide 21: HIV
HIV • Positive results for the combination of doravirine and islatravir • Advancing Phase 3 trials for islatravir in combination with lenacapavir (in collaboration with Gilead) • Developing Phase 3 program for MK-8527 21
Slide 22: Expanding on our legacy of leading-edge science
Expanding on our legacy of leading-edge science Immunology Ophthalmology 22
Slide 23: Immunology: Tulisokibart
Immunology Tulisokibart • Initiated Phase 3 studies in patients with ulcerative colitis and Crohn’s disease • Planning further registrational studies in additional indications 23
Slide 24: Ophthalmology: MK-3000
Ophthalmology MK-3000 • Investigational tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway • Two Phase 3 studies launched • Actively recruiting participants 24
Slide 25: 25
25
Slide 26: Nominees for Director
Nominees for Director Robert M. Douglas M. Mary Ellen Coe Pamela J. Craig Thomas H. Surendralal L. Risa J. Lavizzo- Davis Baker, Jr. Glocer Karsanbhai Mourey, M.D. Stephen L. Paul B. Patricia F. Christine E. Inge G. Thulin Kathy J. Warden Mayo, Ph.D. Rothman, M.D. Russo Seidman, M.D. 26
Slide 27: 27
27
Slide 28: Proposal 4 – Shareholder Proposal
Proposal 4 – Shareholder Proposal 28
Slide 29: 29
29
Slide 30: Proposal 5 – Shareholder Proposal
Proposal 5 – Shareholder Proposal 30
Slide 31: 31
31
Slide 32: Proposal 6 – Shareholder Proposal
Proposal 6 – Shareholder Proposal 32
Slide 33: 33
33
Slide 34: Proposal 7 – Shareholder Proposal
Proposal 7 – Shareholder Proposal 34
Slide 35: 35
35
Slide 36: Question & Answer
Question & Answer 36
Slide 37: 37
37
Slide 38: Thank you
Thank you Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. 38